臨床試験の新たな分析結果から、オゼンピックやウゴービの有効成分であるセマグルチドが、肥満を抱える高齢者の大幅な減量と心血管の健康指標の改善に寄与することが示されました。この知見は、週1回の投与と生活習慣の改善を併用した65歳以上の参加者のデータを基にしたものです。
パドヴァ大学のルカ・ブセット教授らが率いる研究チームは、STEP 1、3、4、5、8、および9の各臨床試験の結果を調査しました。今回の分析では、糖尿病を患っていない肥満の65歳以上の成人358人を対象とし、そのうち248人が68週間にわたりセマグルチド2.4mgを投与され、110人がプラセボを投与されました。
AIによるレポート AIによって生成された画像 事実確認済み
People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.
A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.
AIによるレポート
A real-world study of nearly 8,000 patients by Cleveland Clinic researchers shows that stopping injectable semaglutide or tirzepatide often does not lead to major weight regain. Many participants maintained or continued losing weight by restarting treatment, switching medications, or using lifestyle support. This differs from clinical trials where rapid regain was observed.
Scientists have developed a hybrid obesity treatment that uses GLP-1 and GIP signals to deliver a metabolic enhancer directly into cells. Early tests in mice showed greater weight loss and better blood sugar control than standard therapies. The approach aims to reduce side effects by limiting the drug's action to targeted areas.
AIによるレポート
Young Indians are turning to diabetes drugs Ozempic and Mounjaro for rapid weight loss before weddings and job interviews, as experts warn of cosmetic misuse, grey market dangers, and rising lookism. These GLP-1 drugs are meant for obesity and diabetes, not vanity purposes, doctors emphasize.
A new Karolinska Institutet study finds that children with moderate obesity face higher risks of type 2 diabetes, high blood pressure, and lipid disorders in adulthood, even without apparent risk markers. Researchers urge treatment for all such children.
AIによるレポート 事実確認済み
A University of Connecticut-led clinical trial found that older women recovering from a recent hip fracture who used a topical testosterone gel alongside a structured exercise program did not experience the typical rise in visceral abdominal fat seen during recovery. Researchers followed participants for six months and assessed body composition with imaging scans.